Anna-Lise Williamson | |
---|---|
Education | University of the Witwatersrand Doctor of Philosophy (PhD), Virology |
Scientific career | |
Fields | Virology |
Thesis | An Electron Microscope and Immunocytochemical Study of Jaagsiekte (1985) |
Website | www |
Anna-Lise Williamson FRSSAf MASSAf is a South African virologist. She is a Professor of Virology at the University of Cape Town. [1] Her area of expertise is human papillomavirus, but is also known on an international level for her work in developing vaccines for HIV. These vaccines have been introduce in phase 1 of clinical trial. Williamson has published more than 120 papers. [2]
Williamson received a PhD at the University of the Witwatersrand in 1985. Her Ph.D. thesis was entitled "An Electron Microscopic and Immunocytochemical Study of Jaagsiekte". [3] Williamson was also a fellow at the Royal Society of South Africa [4] and at the University of Cape Town. [2]
Anna-Lise Williamson is the Director of University of the Cape Town vaccine Research group GLP. Her area of expertise and what she is best known for is Human Papillomavirus and HIV Vaccines. [1]
Anna-Lise Williamson is the head of the HIV vaccine development and human papilloma research group at the University of Cape Town. There, Williamson and a team of over 30 people are developing vaccines for HIV-1 subtype C virus. This strain is known to be the most Virulent, [6] and known to be the principle strain that leads to AIDS.The goal of the investigation is to create affordable and effective HIV-1 C vaccines, [7] [8] [9] that would increase the longevity of memory T cells and develop a more functional use of the CD4+ and CD8+ cell response. [2] Two vaccines have been selected to move forward in clinical trials. These vaccines are DNA vaccines and a modified vaccinia virus Ankara vaccine. The vaccines were developed as part of the South African AIDS Vaccine Initiative (SAAVI). [2] [6]
Anna-Lise Williamson has published over 120 papers. Her publications mainly consists of her area of expertise addressing HIV vaccine development, HIV virus, and HPV virus.